

Suven grants exclusive license to Taro Pharmaceuticals

07 March 2014 | News | By BioSpectrum Bureau

Suven grants exclusive license to Taro Pharmaceuticals

Malathion lotion is indicated for patients infected with *Pediculus humanus capitis* (head lice and their ova) of the scalp hair.

In this regard, Taro will pay Suven a royalty and the arrangement is effective until April 2028, unless otherwise terminated.